Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in oligodendrocyte progenitor cells (872 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9205
Sealed predictions
- NLGN4X in dopamine neurons, braak+0.83 (p 0.006) → -0.32 (p 0.407)receipt 9213
- NLGN4X in oligodendrocytes, braak-0.26 (p 0.502) → +0.61 (p 0.083)receipt 9212
Swarm cases
receipt 9213: NLGN4X in dopamine neurons, braak
- power
- full sample +0.28 (p 0.269, n 18), 95% CI -0.22 to +0.66. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.31 (p 0.207, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.33 (p 0.176, n 18). could be the mix.
- skeptic
- leave-one-out range +0.17 to +0.38, sign flips 0; without severely affected donors +0.28 (p 0.269, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NLGN4X in dopamine neurons.
case closed: nothing better to follow up.
receipt 9212: NLGN4X in oligodendrocytes, braak
- power
- full sample +0.05 (p 0.834, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.08 (p 0.748, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.05 (p 0.834, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.16, sign flips 3; without severely affected donors +0.05 (p 0.834, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NLGN4X in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts